

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>BROADWOOD PARTNERS, L.P.</u>  (Last) (First) (Middle) <u>C/O BROADWOOD CAPITAL INC.</u> <u>724 FIFTH AVENUE, 9TH FLOOR</u>  (Street) <u>NEW YORK NY 10019</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Lineage Cell Therapeutics, Inc. [ LCTX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>08/13/2019</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares	08/13/2019		P		10,000	A	\$0.9949 <sup>(3)</sup>	33,990,826	D <sup>(1)</sup>	
Common Shares	08/13/2019		P		0	A	\$0	33,990,826	I	See Footnote <sup>(2)</sup>
Common Shares	08/14/2019		P		1,407	A	\$0.98	33,992,233	D <sup>(1)</sup>	
Common Shares	08/14/2019		P		0	A	\$0	33,992,233	I	See Footnote <sup>(2)</sup>
Common Shares	08/15/2019		P		13,146	A	\$0.9674 <sup>(4)</sup>	34,005,379	D <sup>(1)</sup>	
Common Shares	08/15/2019		P		0	A	\$0	34,005,379	I	See Footnote <sup>(2)</sup>
Common Shares								62,908	D <sup>(5)</sup>	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person<sup>\*</sup>  
BROADWOOD PARTNERS, L.P.

---

(Last) (First) (Middle)  
 C/O BROADWOOD CAPITAL INC.  
 724 FIFTH AVENUE, 9TH FLOOR

---

(Street)  
 NEW YORK NY 10019

---

(City) (State) (Zip)

1. Name and Address of Reporting Person<sup>\*</sup>  
BROADWOOD CAPITAL INC

---

(Last) (First) (Middle)  
 724 FIFTH AVENUE, 9TH FLOOR

---

(Street)  
 NEW YORK NY 10019

---

(City) (State) (Zip)

1. Name and Address of Reporting Person<sup>\*</sup>  
BRADSHER NEAL C

---

(Last) (First) (Middle)  
 C/O BROADWOOD CAPITAL INC.  
 724 FIFTH AVENUE, 9TH FLOOR

---

(Street)  
 NEW YORK NY 10019

---

(City) (State) (Zip)

**Explanation of Responses:**

1. These securities are owned by Broadwood Partners, L.P.
2. The reported securities are directly owned by Broadwood Partners, L.P. and may be deemed to be beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners, L.P. and Neal C. Bradsher as President of Broadwood Capital, Inc. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
3. This constitutes the weighted average purchase price. The prices range from \$0.9857 to \$1.00. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
4. This constitutes the weighted average purchase price. The prices range from \$0.9587 to \$0.97. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
5. These securities are owned by Neal C. Bradsher in his personal capacity.

**Remarks:**

On August 9, 2019, the Issuer amended Article I of its Restated Articles of Incorporation to change its name from "BioTime, Inc." to "Lineage Cell Therapeutics, Inc." In connection with the Issuer's name change, effective as of August 12, 2019, the Issuer's common shares began trading on the NYSE American under the ticker symbol "LCTX".

Broadwood Partners, L.P., By  
Broadwood Capital, Inc., By: 08/15/2019  
/s/ Neal C. Bradsher, President  
Broadwood Capital, Inc., By: 08/15/2019  
/s/ Neal C. Bradsher, President  
/s/ Neal C. Bradsher 08/15/2019  
 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.